evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

24 questions · 24 findings · 3 reviews · Hepato-Biliary

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 8 · 33.3%GRADE not reported 0 · 0%Very low 12 · 50%Low 4 · 16.7%Moderate 0 · 0%High 0 · 0%

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).

1 finding from 1 review